Paracetamol prices in the United States strengthened significantly through March, driven by constrained import availability and steady end-market demand. Supply limitations emerged early in the month as Chinese producers prioritized domestic formulations following the Lunar New Year, while shipments from India were further restricted due to regulatory constraints on select API facilities. These factors reduced export volumes, tightening spot availability in the US market. Demand remained robust across retail, institutional, and manufacturing channels. Increased incidence of seasonal influenza supported higher consumption, while hospitals and distributors accelerated procurement ahead of April formulary cycles. Retail shortages, particularly in pediatric and high-strength formulations, further intensified buying activity and reinforced competitive sourcing behavior. On the cost side, rising feedstock prices, particularly for para-aminophenol and phenol derivatives, increased production expenses. Additionally, elevated freight rates and higher exporter quotations raised landed costs, outweighing any currency-related advantages. Looking ahead, the market is expected to maintain an upward bias in the near term, supported by tight supply conditions, sustained healthcare demand, and ongoing cost pressures, subject to evolving market dynamics.
